Bioprocessing White Papers

  1. Smart Scaling For Cell And Gene Therapies 2/5/2026

    To meet patient demand, advanced therapy manufacturing processes must be commercial ready. CGT sponsors can mitigate risk and protect viability by partnering with a CDMO that prioritizes scalability.

  2. Bispecific Antibodies Unleashed 2/4/2026

    Explore how leveraging expert CDMO partnerships can streamline the development process and enhance the efficacy of your bispecific antibody therapies.

  3. The Current And Future Value Of mRNA Vaccines And Therapeutics 2/4/2026

    Discover how decades of research have propelled mRNA technology to the forefront of therapeutic development and learn how our expertise is advancing mRNA drug development.

  4. The Benefits Of End-To-End Formulation And Fill/Finish Of Biologics 2/4/2026

    Proper formulation development has a huge impact on whether a technology transfer to clinical phase fill/finish is successful. Review the challenges of transitioning a promising drug candidate.

  5. Leveraging Efficiency From CLD To Clinical Manufacturing Of mAbs 2/4/2026

    Discover how our efficient strategies can propel your mAb from discovery to clinical manufacturing in as little as 18 months.

  6. Leveraging The Immunological Diversity Of The Pentamice® Platform For Covid-19 Antibody Discovery 2/4/2026

    Consider this alternative immunization approach — the PentaMice platform, a collection of five wildtype mouse strains bred in-house for increased MHC class II diversity — and how we're leveraging it for COVID-19 antibody discovery.

  7. The Value Of Engaging A Single CDMO For Comprehensive Biologics Services 2/4/2026

    By forging strategic partnerships with comprehensive CDMOs, see how emerging biopharma firms can navigate through early-phase development and ensure a smooth transition to clinical advancement.

  8. Engineering Reliability In Cell Therapy Manufacturing 2/3/2026

    A cell therapy manufacturing model built on precision planning, digital execution, lifecycle‑ready CMC systems, and transparent collaboration to achieve high reliability and reduce variability across programs.

  9. The Power Couple: CRISPR And Oligonucleotides 1/27/2026

    Oligonucleotides are reshaping genetic medicine, with CRISPR accelerating demand for complex gRNA sequences. Learn about the manufacturing challenges that define the next phase of oligo development.

  10. Selecting A CDMO For Custom Activated PEGs 1/27/2026

    Custom-activated PEGs require thoughtful planning and precise analytical control. Discover key considerations for selecting a partner capable of supporting scalable, compliant PEGylation.